Semax ACTH(4-10) Analog: BDNF Upregulation and Neuroprotective Signaling

A detailed mechanistic review of ACTH(4-7)PGP heptapeptide's documented effects on brain-derived neurotrophic factor expression, NGF receptor dynamics, and oxidative stress mitigation in neuronal research models.

Semax — the heptapeptide MEHFPGP, derived from the ACTH(4-10) sequence with a C-terminal PGP extension — represents a structurally optimized research tool compound for probing neurotrophic signaling pathways. Its design incorporates the Met-Glu-His-Phe pharmacophore core responsible for MSH/ACTH receptor engagement, extended by a Pro-Gly-Pro stabilizing tripeptide that substantially increases resistance to prolyl endopeptidase cleavage.

BDNF Induction: Evidence and Mechanistic Basis

Brain-derived neurotrophic factor (BDNF) is arguably the most well-characterized neurotrophin in the central nervous system, with roles spanning synaptic plasticity, neuronal survival, and adult neurogenesis. Multiple independent research groups have reported BDNF mRNA upregulation in rat cortical neuron cultures following Semax treatment, with increases ranging from 1.4 to 2.8-fold depending on concentration and measurement timepoint.

TrkB Receptor Downstream Signaling

BDNF exerts its primary effects through the TrkB (NTRK2) receptor tyrosine kinase. Phosphorylation at TrkB Y515 activates the PI3K/Akt survival pathway, while pY816 engages PLCγ/PKC signaling linked to synaptic potentiation. Semax-induced BDNF upregulation consequently drives secondary TrkB autophosphorylation — creating a positive-feedback amplification loop that extends the neurotrophin signal well beyond the initial peptide exposure window.

Melanocortin Receptor Involvement

While BDNF induction represents a downstream outcome, the upstream receptor pharmacology of Semax involves direct engagement of melanocortin receptors MC4R and, to a lesser extent, MC3R — both of which are expressed in limbic structures and cortical interneurons. MC4R is a Gαs-coupled GPCR, and its activation leads to cAMP/PKA-mediated CREB phosphorylation at Ser133, driving transcription of BDNF exon IV — the dominant BDNF transcript in activity-dependent contexts.

• →MC4R binding affinity (radioligand displacement): Ki = 3.2 nM
• →cAMP accumulation in HEK293/MC4R cells at 10⁻⁷ M: 4.1-fold over basal
• →pCREB (Ser133) in cortical neurons at 30 min: 2.7-fold increase
• →BDNF promoter IV luciferase reporter: 3.1-fold induction at 10⁻⁸ M, 6h
• →Effect blocked by MC4R-selective antagonist HS024: 89% inhibition

Oxidative Stress and Mitochondrial Protection

Beyond BDNF-mediated effects, Semax demonstrates direct antioxidant properties in models of neuronal oxidative stress. In a glutamate excitotoxicity model using primary cortical neurons, Semax pre-treatment at 10⁻⁹ M reduced ROS accumulation (measured by DCFH-DA fluorescence) by 43% and attenuated mitochondrial membrane potential collapse (JC-1 assay) by 38%. These effects were partially independent of MC4R, suggesting a direct peptide-membrane interaction component.

Superoxide dismutase (SOD1) and catalase mRNA were both upregulated in treated cultures, consistent with activation of the Nrf2/ARE antioxidant response element pathway. Nrf2 nuclear translocation, confirmed by immunofluorescence, occurred within 2 hours of Semax treatment — preceding the BDNF response and suggesting parallel, independently initiated cytoprotective mechanisms.

Research Model Considerations

Researchers should note that Semax's activity profile is concentration-dependent in a non-monotonic fashion — a common characteristic of peptidergic compounds at neurotrophin-relevant concentrations. Optimal BDNF induction is typically observed in the 10⁻¹⁰ to 10⁻⁸ M range, with diminishing or neutral effects at higher concentrations. This window should guide experimental design when titrating dose-response relationships in primary neuron models.